View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
April 21, 2016

The week in M&A: Chongqing Sansheng, Recipharm

Chongqing Sansheng has announced that it will acquire a 100% interest in Liaoyuan City Baikang Pharmaceutical for a consideration of $40.13m.

Kemwell

Chongqing Sansheng has announced that it will acquire a 100% interest in Liaoyuan City Baikang Pharmaceutical for a consideration of $40.13m.

The target company is a drug manufacturer, whereas Chongqing Sansheng develops building materials and chemicals.

Recipharm has announced plans to invest its available funds, credit facilities and proceeds from shares issues in a rights offering to acquire certain businesses of a biopharmaceutical contract services company Kemwell Biopharma Pvt Ltd.

The $205.86m acquisition will be funded entirely by Recipharm and will include the target company’s contract development and manufacturing assets in the US, Sweden, India.

The acquisition will enable Recipharm expand its technology and capabilities and international market by developing a strong customer relationship.


Image: Recipharma has annoounced to acquire Kemwell Bipoharma; Photo: courtesy of Kemwell Biopharma.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena